Alterome Therapeutics

Alterome Therapeutics is a private, pre-revenue biotech advancing a novel precision oncology pipeline targeting historically undruggable drivers like KRAS and AKT E17K mutations. Leveraging a team with deep expertise in computational drug design and oncology development, the company has rapidly progressed two internally discovered, first-of-their-kind molecules into clinical trials within four years of its founding. With a strong leadership team and backing from top-tier life science investors, Alterome aims to redefine cancer treatment by targeting specific genetic alterations to improve patient outcomes in high-need oncology indications.

Integrated drug discovery platform combining deep biology/chemistry expertise with advanced computational and physics-based drug design to create alteration-specific small molecule therapies.

In KRAS, competition is fierce with approved G12C inhibitors (Amgen, Mirati) and numerous companies developing inhibitors for other mutations (e.g., G12D) and pan-KRAS approaches. In AKT, while pan-inhibitors exist (e.g., ipatasertib, capivasertib), Alterome is a first-mover with a mutation-specific (E17K) inhibitor, facing potential competition if the target is validated.